The novel oxazolidinone tedizolid phosphate is in late-stage development for acute bacterial skin and skin structure infections (ABSSSIs). Preclinical and phase 1 trials have shown that 200-mg once-daily tedizolid phosphate dosing achieves the appropriate pharmacokinetic goals for optimal antimicrobial effect, and a randomized phase 2 dose-ranging trial confirmed that tedizolid phosphate may be an option for the treatment of ABSSSIs at the 200-mg dose, the lowest effective dose, over a mean of 6.4 days of therapy. In the first of two phase 3 trials, 6 days of 200-mg once-daily oral tedizolid phosphate ( plus 4 days of placebo) was noninferior to 10 days of 600-mg twice-daily oral linezolid when evaluated at both the early (48-to 72-hour assessment) and test-of-cure (7-14 days after the last dose of active or placebo agent was given) time points. Initial results from the second phase 3 trial (intravenous to oral therapy design) confirm the study met all primary and secondary endpoints and continues to add insight into the clinical utility of tedizolid phosphate.
Acute bacterial skin and skin structure infections (ABSSSIs) are a frequent indication for antibiotic therapy and an increasing cause of hospitalization [1, 2] . The majority of ABSSSIs are caused by aerobic Grampositive cocci, including Staphylococcus aureus, and beta-hemolytic streptococci [3] . Since 1960, methicillin resistance in S. aureus has become a critical problem in healthcare and community settings [2, [4] [5] [6] , and the numbers of patients with methicillin-resistant S. aureus (MRSA) skin infections seen in emergency departments have increased in recent years, as have cases of skin abscess [2, 7, 8] . Despite the availability of newer antimicrobial agents [9] , updated recommendations for vancomycin administration [10] , and increased active surveillance and other infection control practices [4] , resistant Gram-positive pathogens continue to challenge the management of ABSSSIs [3, 6] and highlight the critical need for new therapeutic options to combat these multidrug-resistant pathogens.
S. aureus has become the most common pathogen encountered in serious skin infections; it has been estimated that >90% of MRSA infections involve ABSSSIs [11] . Once recognized for distinctive antibiotic susceptibility patterns in community or hospital settings [12, 13] , these niches are increasingly cross-populated, rendering the classic phenotypic assessment of empiric pathogen identification less reliable for clinical use [13, 14] . Novel clones of MRSA with increasing resistance to a broad range of antibiotics continue to emerge in many parts of the world [6, 14] .
Despite the workhorse status of vancomycin [1, 10] , the emergence of strains with rising minimal inhibitory concentrations (MICs), as well as vancomycin-intermediate and vancomycin-resistant S. aureus strains, can compromise the clinical efficacy of vancomycin. As demonstrated in a survey of isolates from clinical trials, treatment failure rates were 48% for isolates with a vancomycin MIC of 0.5 µg/mL and increased to >90% when the MIC was >2.0 µg/mL [15] . Challenges to the implementation of drug-level monitoring and newer dosing recommendations for optimal trough levels [16, 17] continue to present clinical challenges for appropriate use of vancomycin. Recent evidence for daptomycin resistance through cross-resistance to vancomycin [18] and novel resistance pathways [19] raises concerns in clinical practice. Resistance to linezolid, the first member of the oxazolidinone class of antibiotics approved for ABSSSIs, has been reported among staphylococci and enterococci associated with 23S rRNA gene mutations and more recently through the chloramphenicol-florfenicol resistance (cfr) methyltransferase gene [20] [21] [22] , with the potential for widespread dissemination through plasmid exchange [23] . For these reasons, new antimicrobial options that bypass these known resistance mechanisms are urgently needed to treat multidrug-resistant Gram-positive bacteria in both hospital and community settings.
Tedizolid phosphate (TR-701) is a novel oxazolidinone prodrug currently being developed for the treatment of Grampositive infections [24] , including those caused by MRSA, as well as vancomycin-and linezolid-resistant Gram-positive pathogens [20] [21] [22] 25] . With the active moiety, tedizolid, having 4-to 16-fold greater activity than linezolid against Grampositive species (including cfr-positive isolates), a convenient oral formulation with high bioavailability, and once-daily dosing, tedizolid phosphate is an attractive candidate for clinical evaluation in ABSSSIs [20, 23, 24, 26] . During the course of tedizolid phosphate development, US Food and Drug Administration (FDA) guidance on the conduct of skin infection clinical trials shifted from older guidance for complicated skin and soft tissue infection (cSSSI) to a revised and updated guidance on the conduct of studies for ABSSSIs [27] . In the same timeframe, the European Medicines Agency (EMA) updated its guidance [28] , resulting in notable differences in patient identification and in the timing of primary and secondary endpoints between the 2 agencies. Over the last 4 years, the clinical development of tedizolid phosphate has kept pace with these changing guidelines, with the successful completion of numerous phase 1 trials (Table 1) , 2 phase 2 trials (1 cSSSI and 1 ABSSSI) and 2 phase 3 trials in ABSSSIs [32, 33] .
EARLY STUDIES
In a 21-day phase 1 safety trial in subjects aged >18 years, once-daily oral doses of 200, 300, or 400 mg of tedizolid phosphate were well tolerated throughout the study [34, 35] , and hematologic changes similar to those seen with twice-daily 600 mg linezolid were only noted for the 400-mg dose between days 7 and 21 of exposure [35] . Based on extensive preclinical modeling and phase 1 safety results, a phase 2 dose-ranging study was designed to evaluate once-daily tedizolid phosphate on efficacy, safety, and tolerability in patients with cSSSIs [36] . This double-blind study included 188 patients aged 18-75 years who were randomized 1:1:1 to a 200-, 300-, or 400-mg once-daily tedizolid phosphate treatment arm for 5-7 days. Eligible patients presented with abscess, deep extensive cellulitis, or infected wounds (surgical or post-traumatic) that included at least 2 of the following signs and symptoms: drainage, erythema, fluctuance, warmth, pain, tenderness, and swelling, as well as a systemic sign of active infection (oral temperature >38°C, white blood cell count >10 000 cells/µL, or >10% immature neutrophils) when the lesion size was <5 cm in diameter. Abscesses with <2 cm of surrounding induration, erythema, or those that did not require incision and drainage were excluded, as were diabetic foot infections, decubitus ulcer, perirectal abscesses, and device-related and ischemic infections. Direct wound and patient assessments were made at the screening visit (day 1), on days 2, 3, and 5 of therapy, at the end-of-therapy (EOT) visit, and at the test-of-cure (TOC) visit (7-14 days after completing treatment). A long-term follow-up assessment was also included. Blood samples were collected for laboratory, hematologic, and pharmacokinetic modeling of drug disposition.
The primary outcome measure of the study was the clinical response rate (as assessed by the investigator as described by the 1998 cSSSI guidance) of each dose group at the TOC visit in the clinically evaluable and clinical modified intent-to-treat populations. Clinical cure was defined as resolution of the infection or improvement in signs and symptoms of cSSSI such that no further treatment was required. Clinical failure was determined when evidence showed persistent or incomplete resolution of infection or the development of new signs and symptoms such that further antibiotic therapy was needed, an unplanned surgery was required after 48 hours of therapy, a new diagnosis of osteomyelitis was made, or a treatmentlimiting adverse event or patient death occurred. Secondary outcome measures were cure rates at the EOT visit, microbiologic response rates, safety profile of each dose group, and characterization of absorption and disposition of tedizolid using population pharmacokinetic modeling [36] . Across all 3 doses, patient baseline characteristics were well matched for age, sex, race, and infection type. Overall, 77% of the wounds were large abscesses, and 17.6% were cellulitis; 80% required incision and drainage between the screening visit and day 2 of therapy. Overall, lesion diameter was >20 cm for 19.7% of patients; systemic signs and symptoms were documented at baseline in 59% of cases. The mean duration of tedizolid phosphate therapy was 6.4 days. Clinical cure rate was 87.8% in the modified intent-to-treat population, 95.7% in the clinically evaluable population, and 96.2% in the microbiologically evaluable (ME) population. Clinical cure rates were similar not only for all dose groups but also for subgroups based on lesion type, lesion size, and severity of infection (Table 2 ) [36] . The majority of patients (94.7%) completed therapy, and no patient discontinued treatment because of adverse events [36] . Only 3.7% of patients were deemed clinical failures [36] .
Of 196 isolates collected at baseline, the most common pathogen was S. aureus (81.6% of isolates from 90.3% of patients) [25] . Other pathogens included a variety of staphylococcal and streptococcal species. Of the 163 S. aureus isolates, 76% were MRSA (99% positive for Panton-Valentine leukocidin) and 24% were methicillin-sensitive S. aureus (MSSA; 77% positive for PantonValentine leukocidin). Tedizolid MICs for S. aureus were 0.12-0.5 µg/mL (MIC required to inhibit growth of 90% of organisms [MIC 90 ] of 0.25 µg/mL for both MSSA and MRSA) [25] . The low MIC for tedizolid is consistent with findings from a host of previous in vitro studies [20] [21] [22] .
Overall microbiologic eradication rates at the TOC visit were 97.7%, 97.9%, and 95.7% for all pathogens, MRSA, and MSSA, respectively. Persistent infections were detected in 2 patients with MRSA and 1 with MSSA at baseline. Among patients who failed therapy, 3 had MRSA, 1 had MSSA, and 1 was coinfected with Streptococcus sanguinis and Streptococcus acidominimus at baseline [25] . Overall, clinical and microbiologic outcomes were similar for all dosage groups based on lesion type, lesion size, and presence of systemic signs of infection. Furthermore, oral tedizolid administered over 5-7 days was shown to be safe and well tolerated at all doses evaluated in this trial.
PHASE 3 STUDIES
The Efficacy and Safety of 6-day Tedizolid Phosphate vs 10-day Linezolid Therapy for ABSSSI (ESTABLISH) trials were designed and conducted in accordance with new FDA guidance for ABSSSIs (with a primary endpoint at 48-72 hours) and current EMA guidance for assessment of response at EOT and TOC [27, 28] . The recently published ESTABLISH-1 trial [32] compares oral tedizolid phosphate with oral linezolid in patients with ABSSSIs, whereas the ESTABLISH-2 trial compares subjects started on intravenous therapy, with the option to switch to oral therapy [33] . Both studies are randomized, double-blind, multicenter, multinational trials in which patients were treated with either 6 days for tedizolid phosphate (200 mg once daily, plus 4 days of placebo) or 10 days for linezolid (600 mg twice daily). The primary endpoint is programmatic assessment of clinical response (cessation of lesion spread and absence of fever in ESTABLISH-1, or ≥20% reduction in lesion size for ESTABLISH-2) at 48-72 hours after the start of therapy [27, 29, 33] . Both protocol-based (the primary endpoint) and investigator assessment of response are determined at 48-72 hours after the first dose of study medication. Data is also collected at EOT (11 days after the first dose of medication) and TOC, in line with EMA guidance and secondary endpoints in the FDA guidance [27, 28] . As a result, these phase 3 protocols allow a comparison of 200-mg once-daily tedizolid phosphate vs 600-mg twice-daily linezolid on early (48-to 72-hour) wound responses and a comparison of the impact of 6 days of tedizolid phosphate therapy vs 10 days of linezolid therapy on clinical response assessed at more traditional EOT and TOC (or post-therapy evaluation) times.
For the first phase 3 trial, a total of 666 patients from 82 sites in 11 countries across North America, South America, and Europe were randomized 1:1 to treatment. Inclusion criteria included men and women aged >18 years with 1 regional or systemic sign of ABSSSI (lymph node tenderness and increased volume, fever ≥38°C, white blood cell count ≥10 000/µL or <4000/µL, or ≥10% immature neutrophils) and one of the following syndromes [32] :
• Cellulitis with erythema covering at least 75 cm 2 with 1 local sign or symptom (induration, warmth, pain/tenderness, or swelling) (41% of enrolled subjects).
• A major cutaneous abscess with erythema surface area of at least 75 cm 2 and extending at least 5 cm from the margin of pus collection with at least 1 sign or symptom of local infection (fluctuance, requiring incision and drainage, warmth, pain/tenderness) (30% of enrolled subjects).
• A surgical-or trauma-related wound infection with an erythema surface area of at least 75 cm 2 and extending at least 5 cm from the peripheral margin of the wound with purulent drainage (29% of enrolled subjects).
Exclusion criteria included patients with uncomplicated skin and skin structure infections, infections close to prosthetic device, severe sepsis or known bacteremia, surgery other than clean surgery, and exposure to systemic antibiotics with Grampositive cocci activity within the prior 96 hours. Patients were excluded from the cellulitis/erysipelas and major cutaneous abscess groups when a Gram-negative pathogen was suspected or documented. This exclusion was not applied to patients with wound infections; for these individuals, adjunctive aztreonam or metronidazole were allowed in the first 3 days of therapy when suspect or proven Gram-negative anaerobes or aerobes were involved [32] .
Overall there were no differences in patient demographics, infection type (cellulitis/erysipelas, major cutaneous abscess, wound infection), regional or systemic symptoms, or surface area involvement between patients receiving tedizolid phosphate or linezolid at baseline [32] . Baseline lesion surface areas were similar between treatment arms (188 cm  2 and 190 cm   2 ). Regional/systemic signs of infection were similar in both treatment groups; 87% of patients had lymphadenopathy adjacent to the lesion, 41% had white blood cell counts ≥10 000 or <4000 cells/mm 3 , 3% had >10% immature neutrophils, and 18% had temperatures ≥38°C. A summary of the disposition of patients through the course of the ESTABLISH-1 trial is shown in Table 3 .
Analysis of the primary endpoint revealed similar clinical response for tedizolid phosphate (79.5%; 95% confidence interval Adapted with permission from Prokocimer et al [32] . Copyright © 2013 American Medical Association. All rights reserved.
Abbreviations: CE, clinically evaluable; CI, confidence interval; EOT, end of therapy; ITT, intent-to-treat; PTE, post-therapy evaluation. a For the investigator's assessment of clinical response, clinical success was defined as meeting these 3 criteria: (1) resolution or near resolution of most disease-specific signs and symptoms; (2) absence or near resolution of systemic signs of infection (lymphadenopathy, fever, >10% immature neutrophils, abnormal white blood cell count), if present at baseline; and (3) no new signs, symptoms, or complications attributable to the ABSSSIs so no further antibiotic therapy was required for the treatment of the primary lesion.
[CI], 74.8 to 83.7) and linezolid (79.4%, 95% CI, 74.7% to 83.6%) at 48-72 hours after initiating study treatment (Table 4) . Clinical response was defined as an afebrile patient who had cessation of the primary ABSSSI lesion spread (measured as surface area of lesion involvement). Reasons a patient was determined to be a nonresponder at the primary endpoint evaluation were missing data in the tedizolid phosphate (11.1%) or linezolid (9.6%) arms or a true clinical nonresponse (spread of the primary lesion or temperature >37.6°C), which occurred in 8.1% of the tedizolid group and 10.4% of the linezolid group. There was high concordance (>80%) between the programmatic outcome at the 48-to 72-hour time point and the investigator assessment of clinical response at post-therapy evaluation [32] . A sustained clinical response was also observed at EOT by programmatic or investigator-based assessment (Table 4) . Attributes for sustained clinical response at EOT included the primary endpoint criteria plus the absence of patient-reported pain and/or tenderness that was worse than "mild." Sensitivity analysis was undertaken to test the robustness of the data and to correspond with evolving regulatory guidance. This analysis excluded temperature as an outcome determinant for the primary endpoint or the pain criteria for the EOT endpoint ( Table 5 ). The analysis showed that excluding temperature and varying the lesion response definition from cessation of lesion spread to ≥20% reduction in lesion size did not change the outcome at the primary endpoint, and exclusion of the pain criteria (as reported in the 2010 ABSSSI draft guideline [27] ) did not alter outcome at the EOT visit. A pathogen was isolated from the primary infection site in approximately 63% of patients. The most common pathogen isolated was S. aureus (82.8%), with MRSA accounting for 42.1% of infections in the tedizolid phosphate group and 43.1% of infections in the linezolid group [32] .
Safety data were recorded for all patients who received at least 1 dose of study medication. Patients receiving 200-mg oral tedizolid phosphate once-daily experienced similar rates of overall adverse events and treatment-emergent adverse events compared with patients receiving 600-mg oral linezolid twicedaily in the phase 3 trial. A significant trend toward lower gastrointestinal treatment-emergent adverse events was observed in the tedizolid phosphate-treated group, and fewer abnormally low platelet counts were observed in the analysis of hematology laboratory data in the tedizolid phosphate group [37] .
Initial data from the second phase 3 clinical trial, comparing the early clinical response rate of intravenous to oral 6-day tedizolid phosphate with that of intravenous to oral 10-day linezolid (48-72 hours after the first infusion of study drug) for the treatment of ABSSSIs [38] , have recently been reported [33] . In this trial, patients start treatment with at least 2 intravenous doses and may receive intravenous therapy for the entire treatment duration. Patients aged >12 years were recruited and randomized 1:1 to study treatment. Inclusion criteria include patients requiring intravenous antibiotic therapy and with systemic signs of infection diagnosed with ABSSSI, and the diagnoses of cellulitis/erysipelas, major cutaneous abscess, or wound infections. Exclusion criteria are similar to the first Phase 3 trial [38] . Initial data analysis confirms that the ESTABLISH-2 trial met all primary and secondary endpoints set by the FDA and EMA for evaluation of new antibiotics in ABSSSI [33] .
DISCUSSION
Single-and multiple-dose phase 1 trials, a dose-ranging phase 2 trial, and 2 phase 3 trials comparing tedizolid phosphate and linezolid under the rubric of new FDA and EMA guidance for ABSSSI trials have been completed. Throughout late-stage development of tedizolid phosphate, trial protocols have stayed abreast of new draft FDA and EMA guidance [27, 28] and recommendations for primary endpoint timing and assessment protocols [39] . The FDA's Special Protocol Assessment approval for the first phase 3 trial ( June 2010) [40] came just months before the FDA released its draft guidance on developing drugs for the treatment of ABSSSIs (August 2010) [27] . In August 2011, Trius received Special Protocol Assessment approval for the second phase 3 trial [41] , and in the same month the Foundation for the National Institutes of Health (FNIH) submitted its recommendations on ABSSSI guidance [39] . Throughout this process, Trius has prospectively collected the data needed to fully address the proposed primary and secondary endpoints identified in current FDA and EMA guidelines.
As a novel oxazolidinone, tedizolid phosphate offers enhanced potency against significant Gram-positive pathogens and low intrinsic rates of resistance formation [24] . Despite higher protein binding compared with linezolid, recent microdialysis studies confirm effective delivery of tedizolid to the interstitial fluid spaces of skeletal muscle and subcutaneous fat [42] .
In a neutropenic mouse thigh S. aureus infection model, tedizolid phosphate administration achieved a greater MSSA and MRSA burden reduction at 24 and 48 hours than did equal doses of linezolid, and doses >40 mg/kg tedizolid phosphate lowered burden below levels anticipated for a static antibiotic, consistent with in vivo bactericidal activity [26] . The stasis threshold could not be achieved by linezolid doses up to 150 mg/kg/d at either 24 or 48 hours. Beyond free drug delivery to target tissues, tedizolid accumulation into granulocytes is greater than the accumulation of linezolid [43] , an attribute that may further contribute to the in vivo activity of tedizolid for select immune-competent patients, particularly for infections of skin and soft tissues where early granulocyte migration is an important attribute of host response.
Available data from phase 1, 2, and 3 trials have demonstrated the relative clinical efficacy and safety profile for tedizolid phosphate. These trials have also begun to illustrate the potential for attributes of tedizolid phosphate to improve the management of serious Gram-positive infections, including lower overall drug exposure, once-daily oral dosing (without regard to meals), predictable drug pharmacokinetics, and a favorable safety profile. The phase 2 dose-ranging study demonstrated comparable efficacy results across the 200-mg, 300-mg, and 400-mg tedizolid phosphate doses over 5-7 days of treatment for ABSSSIs [25] , leading to the selection of the lowest effective dose of 200-mg once-daily for the phase 3 trials. Results from both phase 3 trials confirmed that 200-mg once-daily tedizolid phosphate met all noninferiority endpoint criteria as described by current FDA and EMA guidance for the treatment of ABSSSIs. The microbiologic response data are consistent with the documented in vitro activity profile for tedizolid, whereas the accumulating safety database has confirmed that tedizolid phosphate is a promising agent for clinical use.
Although the overall patient populations in the phase 2 and 3 tedizolid phosphate trials may differ somewhat from those studied in the recently completed comparison of linezolid and vancomycin in complicated MRSA skin infections (which included diabetic foot infections but not cellulitis) [44] , they are similar to the population in the ceftaroline registration trial [45] and a recent multicenter observational report [1] . In the later study, approximately 90% of patients presented with erythema, tenderness, pain, or local warmth, whereas only 8.2% were recorded to have a temperature >38°C, observations that are consistent with the patient demographics in the recently completed phase 3 trial population [32] . Although 88.8% of patients in the observation study were started on intravenous antibiotics (for 2-3 days), most were either switched to another formulation (53.6%) or discontinued treatment based on improved infections (43.6%) before discharge, which on average was at 7.1 days. These characteristics of patients hospitalized with ABSSSIs are well matched to the emerging evidence that tedizolid may be an oral option for the management of ABSSSIs that was shown to be well tolerated in clinical trials.
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